{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T18:48:02Z","timestamp":1788029282653,"version":"build-2784847793"},"reference-count":79,"publisher":"SAGE Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JHD"],"published-print":{"date-parts":[[2016,3,31]]},"DOI":"10.3233\/jhd-160196","type":"journal-article","created":{"date-parts":[[2016,3,31]],"date-time":"2016-03-31T17:15:21Z","timestamp":1459444521000},"page":"1-13","source":"Crossref","is-referenced-by-count":78,"title":["Cerebrospinal Fluid Biomarkers for Huntington\u2019s Disease"],"prefix":"10.1177","volume":"5","author":[{"given":"Lauren M.","family":"Byrne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward J.","family":"Wild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JHD-160196_ref1","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1002\/mds.26007","article-title":"Targets for future clinical trials in Huntington\u2019s disease: What\u2019s in the pipeline?","volume":"29","author":"Wild","year":"2014","journal-title":"Mov Disord"},{"key":"10.3233\/JHD-160196_ref2","doi-asserted-by":"crossref","unstructured":"The Huntington\u2019s Disease Collaborative Research GrouA novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes. Cell. 1993;72:971\u201383.","DOI":"10.1016\/0092-8674(93)90585-E"},{"key":"10.3233\/JHD-160196_ref3","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/nrneurol.2014.24","article-title":"Huntington disease: Natural history, biomarkers and prospects for therapeutics","volume":"10","author":"Ross","year":"2014","journal-title":"Nat Rev Neurol"},{"key":"10.3233\/JHD-160196_ref5","doi-asserted-by":"crossref","unstructured":"Huntington Study GrouUnified Huntington\u2019s disease rating scale: Reliability and consistency. Mov Disord. 1996;11(2):136\u201342.","DOI":"10.1002\/mds.870110204"},{"key":"10.3233\/JHD-160196_ref6","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1517\/17530059.2012.701205","article-title":"Biomarkers for Huntington\u2019s disease: An update","volume":"6","author":"Scahill","year":"2012","journal-title":"Expert Opin Med Diagn"},{"key":"10.3233\/JHD-160196_ref7","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3389\/fneur.2015.00179","article-title":"A Practical Guide to Immunoassay Method Validation","volume":"6","author":"Andreasson","year":"2015","journal-title":"Front Neurol"},{"key":"10.3233\/JHD-160196_ref8","first-page":"1","article-title":"Guideline on bioanalytical method validation","volume":"44","author":"EMA","year":"2012","journal-title":"EMEA, Comm Med Prod Hum Use"},{"key":"10.3233\/JHD-160196_ref9","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1474-4422(11)70263-0","article-title":"Potential endpoints for clinical trials in premanifest and early Huntington\u2019s disease in the TRACK-HD study: Analysis of 24-month observational data","volume":"11","author":"Tabrizi","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.3233\/JHD-160196_ref10","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S1474-4422(13)70088-7","article-title":"Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington\u2019s disease in the TRACK-HD study: Analysis of 36-month observational data","volume":"12","author":"Tabrizi","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.3233\/JHD-160196_ref14","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1517\/17530059.2.1.47","article-title":"Biomarkers for Huntington\u2019s disease","volume":"2","author":"Wild","year":"2008","journal-title":"Expert Opin Med Diagn"},{"key":"10.3233\/JHD-160196_ref15","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1084\/jem.20080178","article-title":"A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington\u2019s disease","volume":"205","author":"Bj\u00f6rkqvist","year":"2008","journal-title":"J Exp Med"},{"key":"10.3233\/JHD-160196_ref16","doi-asserted-by":"crossref","first-page":"e647","DOI":"10.1371\/journal.pone.0000647","article-title":"Early energy deficit in Huntington disease: Identification of a plasma biomarker traceable during disease progression","volume":"2","author":"Mochel","year":"2007","journal-title":"PLoS One"},{"key":"10.3233\/JHD-160196_ref17","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/ajmg.b.30501","article-title":"Low brain-derived neurotrophic factor (BDNF) levels in serum of Huntington\u2019s disease patients","volume":"144","author":"Ciammola","year":"2007","journal-title":"Am J Med Genet Part B Neuropsychiatr Genet"},{"key":"10.3233\/JHD-160196_ref18","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1055\/s-0037-1613072","article-title":"Brain-derived neurotrophic factor is stored in human platelets and released by agonist stimulation","volume":"87","author":"Fujimura","year":"2002","journal-title":"Thromb Haemost"},{"key":"10.3233\/JHD-160196_ref19","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.1172\/JCI64565","article-title":"Mutant huntingtin fragmentation in immune cells tracks Huntington\u2019s disease progression","volume":"122","author":"Weiss","year":"2012","journal-title":"J Clin Invest"},{"key":"10.3233\/JHD-160196_ref20","first-page":"79","article-title":"Proteins in cerebrospinal fluid and blood: Barriers, CSF flow rate and source-related dynamics","volume":"21","author":"Reiber","year":"2003","journal-title":"Restor Neurol Neurosci"},{"key":"10.3233\/JHD-160196_ref21","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/YCO.0b013e32835f6747","article-title":"Cerebrospinal fluid biomarkers for pathological processes in Alzheimer\u2019s disease","volume":"26","author":"Ros\u00e9n","year":"2013","journal-title":"Curr Opin Psychiatry"},{"key":"10.3233\/JHD-160196_ref22","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1212\/WNL.0000000000001098","article-title":"CSF biomarkers and clinical progression of Parkinson disease","volume":"84","author":"Hall","year":"2015","journal-title":"Neurology"},{"key":"10.3233\/JHD-160196_ref23","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/01.wad.0000194014.43575.fd","article-title":"Safety and acceptability of the research lumbar puncture","volume":"19","author":"Peskind","year":"2005","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.3233\/JHD-160196_ref24","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1111\/j.1471-4159.1977.tb10676.x","article-title":"\u03b3-Aminobutyric acid (GABA) in human cerebrospinal fluid: Radioreceptor assay","volume":"28","author":"Enna","year":"1977","journal-title":"J Neurochem"},{"key":"10.3233\/JHD-160196_ref25","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1001\/archneur.1977.00500230053008","article-title":"Cerebrospinal fluid gamma-aminobutyric acid variations in neurological disorders","volume":"34","author":"Enna","year":"1977","journal-title":"Arch Neurol"},{"key":"10.3233\/JHD-160196_ref26","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1001\/archneur.1978.00500350032006","article-title":"Huntington\u2019s disease: Cerebrospinal fluid GABA levels in at-risk individuals","volume":"35","author":"Manyam","year":"1978","journal-title":"Arch Neurol"},{"key":"10.3233\/JHD-160196_ref27","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/0024-3205(80)90244-1","article-title":"Cerebrospinal fluid homocarnosine in Huntington\u2019s disease","volume":"26","author":"B\u00f6hlen","year":"1980","journal-title":"Life Sci"},{"key":"10.3233\/JHD-160196_ref28","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/mds.870020206","article-title":"Cerebrospinal fluid GABA and homocarnosine concentrations in patients with Friedreich\u2019s ataxia, Parkinson\u2019s disease, and Huntington\u2019s chorea","volume":"2","author":"Bonnet","year":"1987","journal-title":"Mov Disord"},{"key":"10.3233\/JHD-160196_ref29","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/0024-3205(80)90089-2","article-title":"Effect of isoniazid on cerebrospinal fluid and plasma GABA levels in Huntington\u2019s disease","volume":"26","author":"Manyam","year":"1980","journal-title":"Life Sci"},{"key":"10.3233\/JHD-160196_ref30","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1212\/WNL.31.2.207","article-title":"Treatment of Huntington disease with gamma-acetylenic GABA, an irreversible inhibitor of GABA-transaminase: Increased CSF GABA and homocarnosine without clinical amelioration","volume":"31","author":"Tell","year":"1981","journal-title":"Neurology"},{"key":"10.3233\/JHD-160196_ref31","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/0006-8993(87)90364-7","article-title":"Isoniazid-induced alteration of CSF neurotransmitter amino acids in Huntington\u2019s disease","volume":"408","author":"Manyam","year":"1987","journal-title":"Brain Res"},{"key":"10.3233\/JHD-160196_ref32","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/ana.410100107","article-title":"Isoniazid-induced elevation of CSF GABA levels and effects on chorea in Huntington\u2019s disease","volume":"10","author":"Manyam","year":"1981","journal-title":"Ann Neurol"},{"key":"10.3233\/JHD-160196_ref33","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/BF00314742","article-title":"Cerebrospinal fluid acetylcholinesterase and choline measurements in Huntington\u2019s disease","volume":"237","author":"Manyam","year":"1990","journal-title":"J Neurol"},{"key":"10.3233\/JHD-160196_ref34","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/BF00343834","article-title":"Huntington\u2019s disease - imbalance of free amino acids in the cerebrospinal fluid of patients and offspring at-risk","volume":"231","author":"Oepen","year":"1982","journal-title":"Arch Psychiatr Nervenkr"},{"key":"10.3233\/JHD-160196_ref35","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1159\/000114017","article-title":"A pharmacologic analysis of Huntington\u2019s chorea","volume":"4","author":"Klawans","year":"1970","journal-title":"Eur Neurol"},{"key":"10.3233\/JHD-160196_ref36","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/0022-510X(71)90032-3","article-title":"Cerebrospinal fluid homovanillic acid in Huntington\u2019s chorea","volume":"13","author":"Klawans","year":"1971","journal-title":"J Neurol Sci"},{"key":"10.3233\/JHD-160196_ref37","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1600-0447.1974.tb08912.x","article-title":"Cerebrospinal homovanillic acid and 5-hydroxy-indoleacetic acid in huntington\u2019s chorea","volume":"50","author":"Mattsson","year":"1974","journal-title":"Acta Psychiatr Scand"},{"key":"10.3233\/JHD-160196_ref38","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1136\/jnnp.35.4.514","article-title":"Amine metabolites in the cerebrospinal fluid in Huntington\u2019s chorea","volume":"35","author":"Curzon","year":"1972","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.3233\/JHD-160196_ref39","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1471-4159.1992.tb09283.x","article-title":"Increased cerebrospinal fluid dopamine and 3,4-dihydroxyphenylacetic acid levels in Huntington\u2019s disease: Evidence for an overactive dopaminergic brain transmission","volume":"58","author":"Garrett","year":"1992","journal-title":"J Neurochem"},{"key":"10.3233\/JHD-160196_ref40","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/00002826-199502000-00007","article-title":"Cerebrospinal fluid homovanillic acid is reduced in untreated Huntington\u2019s disease","volume":"18","author":"Garc\u00eda Ruiz","year":"1995","journal-title":"Clin Neuropharmacol"},{"key":"10.3233\/JHD-160196_ref41","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0197-0186(01)00058-4","article-title":"Cross linking of polyglutamine domains catalyzed by tissue transglutaminase is greatly favored with pathological-length repeats: Does transglutaminase activity play a role in (CAG)n\/Qn-expansion diseases?","volume":"40","author":"Cooper","year":"2002","journal-title":"Neurochem Int"},{"key":"10.3233\/JHD-160196_ref42","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1046\/j.1471-4159.2001.00673.x","article-title":"N\u025b-(\u03b3-l-Glutamyl)-l-lysine (GGEL) is increased in cerebrospinal fluid of patients with Huntington\u2019s disease","volume":"79","author":"Jeitner","year":"2001","journal-title":"J Neurochem"},{"key":"10.3233\/JHD-160196_ref43","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1471-4159.2008.05350.x","article-title":"Increased levels of gamma-glutamylamines in Huntington disease CSF","volume":"106","author":"Jeitner","year":"2008","journal-title":"J Neurochem"},{"key":"10.3233\/JHD-160196_ref45","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/nrd3793","article-title":"Kynurenines in the CNS: Recent advances and new questions","volume":"12","author":"V\u00e9csei","year":"2013","journal-title":"Nat Rev Drug Discov"},{"key":"10.3233\/JHD-160196_ref46","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1111\/j.1471-4159.2010.06675.x","article-title":"Dysfunctional kynurenine pathway metabolism in the R6\/2 mouse model of Huntington\u2019s disease","volume":"113","author":"Sathyasaikumar","year":"2010","journal-title":"J Neurochem"},{"key":"10.3233\/JHD-160196_ref47","doi-asserted-by":"crossref","first-page":"9772","DOI":"10.3390\/ijms16059772","article-title":"Changing the face of kynurenines and neurotoxicity: Therapeutic considerations","volume":"16","author":"Boh\u00e1r","year":"2015","journal-title":"Int J Mol Sci"},{"key":"10.3233\/JHD-160196_ref48","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/ana.410240417","article-title":"Cerebrospinal fluid levels of quinolinic acid in Huntington\u2019s disease and schizophrenia","volume":"24","author":"Schwarcz","year":"1988","journal-title":"Ann Neurol"},{"key":"10.3233\/JHD-160196_ref49","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/0304-3940(91)90874-S","article-title":"Regional brain and cerebrospinal fluid quinolinic acid concentrations in Huntington\u2019s disease","volume":"122","author":"Heyes","year":"1991","journal-title":"Neurosci Lett"},{"key":"10.3233\/JHD-160196_ref50","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1093\/brain\/115.5.1249","article-title":"Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease","volume":"115","author":"Heyes","year":"1992","journal-title":"Brain"},{"issue":"4","key":"10.3233\/JHD-160196_ref51","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1111\/j.1471-4159.1990.tb03143.x","article-title":"Kynurenine pathway measurements in Huntington\u2019s disease striatum: Evidence for reduced formation of kynurenic acid","volume":"55","author":"Beal","year":"1990","journal-title":"J Neurochem"},{"key":"10.3233\/JHD-160196_ref52","first-page":"376","article-title":"Oxidative stress in neurodegenerative diseases","volume":"7","author":"Chen","year":"2012","journal-title":"Neural Regen Res"},{"key":"10.3233\/JHD-160196_ref53","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1212\/WNL.52.5.1104","article-title":"Cerebrospinal fluid F2-isoprostanes are elevated in Huntington\u2019s disease","volume":"52","author":"Montine","year":"1999","journal-title":"Neurology"},{"key":"10.3233\/JHD-160196_ref54","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1002\/ana.410440322","article-title":"Cerebrospinal fluid F2-isoprostane levels are increased in Alzheimer\u2019s disease","volume":"44","author":"Montine","year":"1998","journal-title":"Ann Neurol"},{"key":"10.3233\/JHD-160196_ref55","first-page":"1582","article-title":"Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: The TREND-HD study","volume":"65","author":"Huntington Study Group TREND-HD Investigators","year":"2008","journal-title":"Arch Neurol"},{"key":"10.3233\/JHD-160196_ref57","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1021\/pr0700753","article-title":"Proteomic profiling of plasma in Huntington\u2019s disease reveals neuroinflammatory activation and biomarker candidates","volume":"6","author":"Dalrymple","year":"2007","journal-title":"J Proteome Res"},{"key":"10.3233\/JHD-160196_ref58","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1093\/brain\/awt355","article-title":"HTT-lowering reverses Huntington\u2019s disease immune dysfunction caused by NF\u03baB pathway dysregulation","volume":"137","author":"Tr\u00e4ger","year":"2014","journal-title":"Brain"},{"key":"10.3233\/JHD-160196_ref59","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1021\/ci970236v","article-title":"Homology modeling of glycosyl hydrolase family 18 enzymes and proteins","volume":"37","author":"Aronson","year":"1997","journal-title":"J Chem Inf Comput Sci"},{"key":"10.3233\/JHD-160196_ref60","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/j.parkreldis.2014.08.011","article-title":"YKL-40 in cerebrospinal fluid in Huntington\u2019s disease\u2013a role in pathology or a nonspecific response to inflammation?","volume":"20","author":"Vinther-Jensen","year":"2014","journal-title":"Parkinsonism Relat Disord"},{"key":"10.3233\/JHD-160196_ref61","doi-asserted-by":"crossref","first-page":"e15809","DOI":"10.1371\/journal.pone.0015809","article-title":"Increased prothrombin, apolipoprotein A-IV, and haptoglobin in the cerebrospinal fluid of patients with Huntington\u2019s disease","volume":"6","author":"Huang","year":"2011","journal-title":"PLoS One"},{"key":"10.3233\/JHD-160196_ref62","first-page":"225","article-title":"Abnormal penetration of haptoglobin through the blood-brain-barrier (BBB) into the cerebro-spinal fluid (CSF) in Alzheimer\u2019s disease patients","volume":"81","author":"Pantoni","year":"1995","journal-title":"Acta Neurol Scand"},{"key":"10.3233\/JHD-160196_ref63","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1089\/0897715041526212","article-title":"Proteome study of human cerebrospinal fluid following traumatic brain injury indicates fibrin(ogen) degradation products as trauma-associated markers","volume":"21","author":"Conti","year":"2004","journal-title":"J Neurotrauma"},{"key":"10.3233\/JHD-160196_ref64","doi-asserted-by":"crossref","first-page":"49","DOI":"10.17925\/ENR.2010.05.02.49","article-title":"The role of hypothalamic and neuroendocrine changes in the pathogenesis of huntington\u2019s disease \u2013 Current understanding and implications for future treatments","volume":"5","author":"Peters\u00e9n","year":"2010","journal-title":"Eur Neurol Rev"},{"key":"10.3233\/JHD-160196_ref65","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1126\/science.6334362","article-title":"Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients","volume":"226","author":"Nemeroff","year":"1984","journal-title":"Science"},{"key":"10.3233\/JHD-160196_ref66","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/978-1-4684-1039-6_47","volume-title":"Neurobiol. Cerebrospinal Fluid","author":"Post","year":"1980"},{"key":"10.3233\/JHD-160196_ref67","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1001\/archneur.1988.00520320071018","article-title":"Cerebrospinal fluid correlates of depression in Huntington\u2019s disease","volume":"45","author":"Kurlan","year":"1988","journal-title":"Arch Neurol"},{"key":"10.3233\/JHD-160196_ref68","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1530\/eje.0.1510451","article-title":"Circulating and cerebrospinal fluid ghrelin and leptin: Potential role in altered body weight in Huntington\u2019s disease","volume":"151","author":"Popovic","year":"2004","journal-title":"Eur J Endocrinol"},{"key":"10.3233\/JHD-160196_ref69","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.brainres.2005.09.028","article-title":"Normal hypocretin-1 (orexin-A) levels in the cerebrospinal fluid of patients with Huntington\u2019s disease","volume":"1063","author":"Meier","year":"2005","journal-title":"Brain Res"},{"key":"10.3233\/JHD-160196_ref70","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/j.1399-0004.2006.00636.x","article-title":"Cerebrospinal fluid levels of orexin-A are not a clinically useful biomarker for Huntington disease","volume":"70","author":"Bj\u00f6rkqvist","year":"2006","journal-title":"Clin Genet"},{"key":"10.3233\/JHD-160196_ref71","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1093\/sleep\/28.12.1607","article-title":"CSF hypocretin levels are normal in Huntington\u2019s disease patients","volume":"28","author":"Gaus","year":"2005","journal-title":"Slee"},{"key":"10.3233\/JHD-160196_ref72","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1002\/mds.21447","article-title":"Cocaine- and amphetamine-regulated transcript is increased in Huntington disease","volume":"22","author":"Bj\u00f6rkqvist","year":"2007","journal-title":"Mov Disord"},{"key":"10.3233\/JHD-160196_ref73","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s00401-010-0742-6","article-title":"Changes in key hypothalamic neuropeptide populations in Huntington disease revealed by neuropathological analyses","volume":"120","author":"Gabery","year":"2010","journal-title":"Acta Neuropathol"},{"key":"10.3233\/JHD-160196_ref74","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrneurol.2010.4","article-title":"Cerebrospinal fluid and plasma biomarkers in Alzheimer disease","volume":"6","author":"Blennow","year":"2010","journal-title":"Nat Rev Neurol"},{"key":"10.3233\/JHD-160196_ref75","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.parkreldis.2008.05.012","article-title":"Levels of the light subunit of neurofilament triplet protein in cerebrospinal fluid in Huntington\u2019s disease","volume":"15","author":"Constantinescu","year":"2009","journal-title":"Parkinsonism Relat Disord"},{"key":"10.3233\/JHD-160196_ref76","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.parkreldis.2011.06.010","article-title":"Increased levels of total tau protein in the cerebrospinal fluid in Huntington\u2019s disease","volume":"17","author":"Constantinescu","year":"2011","journal-title":"Parkinsonism Relat Disord"},{"key":"10.3233\/JHD-160196_ref77","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1373\/clinchem.2005.058776","article-title":"Effect of sample collection tubes on cerebrospinal fluid concentrations of tau proteins and amyloid \u03b2 peptides","volume":"52","author":"Lewczuk","year":"2005","journal-title":"Clin Chem"},{"key":"10.3233\/JHD-160196_ref78","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1515\/cclm-2013-0293","article-title":"Identification of an important potential confound in CSF AD studies: Aliquot volume","volume":"51","author":"Toombs","year":"2013","journal-title":"Clin Chem Lab Med"},{"key":"10.3233\/JHD-160196_ref79","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ygeno.2005.04.008","article-title":"Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues","volume":"86","author":"Ge","year":"2005","journal-title":"Genomics"},{"key":"10.3233\/JHD-160196_ref80","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1074\/mcp.M800231-MCP200","article-title":"Brain-specific proteins decline in the cerebrospinal fluid of humans with Huntington disease","volume":"8","author":"Fang","year":"2009","journal-title":"Mol Cell Proteomics"},{"issue":"10","key":"10.3233\/JHD-160196_ref81","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1111\/ene.12750","article-title":"Ubiquitin: A potential cerebrospinal fluid progression marker in Huntington\u2019s disease","volume":"22","author":"Vinther-Jensen","year":"2015","journal-title":"Eur J Neurol"},{"key":"10.3233\/JHD-160196_ref82","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3389\/fnmol.2014.00070","article-title":"The ubiquitin-proteasome system in neurodegenerative diseases: Precipitating factor, yet part of the solution","volume":"7","author":"Dantuma","year":"2014","journal-title":"Front Mol Neurosci"},{"key":"10.3233\/JHD-160196_ref83","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1172\/JCI80743","article-title":"Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington\u2019s disease patients","volume":"125","author":"Wild","year":"2015","journal-title":"J Clin Invest"},{"key":"10.3233\/JHD-160196_ref84","doi-asserted-by":"crossref","first-page":"12166","DOI":"10.1038\/srep12166","article-title":"Ultrasensitive measurement of huntingtin protein in cerebrospinal fluid demonstrates increase with Huntington disease stage and decrease following brain huntingtin suppression","volume":"5","author":"Southwell","year":"2015","journal-title":"Sci Rep"},{"key":"10.3233\/JHD-160196_ref85","first-page":"1","article-title":"Huntington\u2019s disease cerebrospinal fluid seeds aggregation of mutant huntingtin","author":"Tan","year":"2015","journal-title":"Mol Psychiatry"}],"container-title":["Journal of Huntington's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JHD-160196","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:57:08Z","timestamp":1777453028000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JHD-160196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,31]]},"references-count":79,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.3233\/jhd-160196","relation":{},"ISSN":["1879-6397","1879-6400"],"issn-type":[{"value":"1879-6397","type":"print"},{"value":"1879-6400","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,31]]}}}